Tandile Hermanus

Johannesburg, GT 2192, South Africa

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.

Journal: medRxiv : the preprint server for health sciences
Published: September 29, 2025

Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.

Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 22, 2025

Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.

Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.

Journal: Frontiers in immunology
Published: May 13, 2025

SARS-CoV-2 vaccines elicit differential Fc effector functions.

SARS-CoV-2 vaccines elicit differential Fc effector functions.

Journal: iScience
Published: January 15, 2025

Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge.

Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge.

Journal: Viruses
Published: December 05, 2024

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern.

Journal: Scientific reports
Published: November 13, 2024

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.

Journal: Viruses
Published: November 12, 2024

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Journal: PLOS global public health
Published: December 04, 2023

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Journal: medRxiv : the preprint server for health sciences
Published: December 04, 2023

Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.

Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.

Journal: Vaccine
Published: September 11, 2023

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.

Journal: PLoS pathogens
Published: June 07, 2023

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.

Journal: Frontiers in immunology
Published: May 30, 2023
Showing 1-12 of 43

Last Updated: 09/26/2026